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Abstract
These guidelines update the previous EANM 2009 guidelines on the diagnosis of pulmonary embolism (PE). Relevant new
aspects are related to (a) quantification of PE and other ventilation/perfusion defects; (b) follow-up of patients with PE; (c)
chronic PE; and (d) description of additional pulmonary physiological changes leading to diagnoses of left ventricular heart
failure (HF), chronic obstructive pulmonary disease (COPD) and pneumonia. The diagnosis of PE should be reported when a
mismatch of one segment or two subsegments is found. For ventilation, Technegas or krypton gas is preferred over diethylene
triamine pentaacetic acid (DTPA) in patients with COPD. Tomographic imaging with V/PSPECT has higher sensitivity and
specificity for PE compared with planar imaging. Absence of contraindications makes V/PSPECT an essential method for the
diagnosis of PE.WhenV/PSPECT is combinedwith a low-dose CT, the specificity of the test can be further improved, especially in
patients with other lung diseases. Pitfalls in V/PSPECT interpretation are discussed. In conclusion, V/PSPECT is strongly recom-
mended as it accurately establishes the diagnosis of PE even in the presence of diseases like COPD, HF and pneumonia and has
no contraindications.
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CTEPH Chronic thromboembolic
pulmonary hypertension
DTPA Diethylene triamine pentaacetic acid
DVT Deep venous thrombosis
EANM European Association of Nuclear Medicine
ELISA Enzyme-linked immunosorbent assay
ESC European Society of Cardiology
81mKr Radioactive krypton gas
MAA Macroaggregated human albumin
NPV Negative prediction value
OSEM Ordered subset expectation maximisation
PE Pulmonary embolism
PERC Pulmonary embolism rule-out criteria
PIOPED Prospective investigation of
pulmonary embolism diagnosis
PPV Positive predicitive value
SNMMI The Society of Nuclear
Medicine and Molecular Imaging
99mTc-DTPA 99mTc-diethylen-tetraamino-pentaacetate
V/PPLANAR Ventilation and perfusion scan
with planar imaging
V/PSCAN Ventilation and perfusion scan
V/PSPECT Ventilation and perfusion single-photon
emission tomography
VTE Venous thromboembolism
Preamble The European Association of Nuclear Medicine
(EANM) will periodically develop new guidelines for nuclear
medicine practice to promote the science of nuclear medicine
and to improve the quality of service to patients throughout
Europe. Each practice guideline, representing an EANM pol-
icy statement, has undergone an extensive consensus and re-
view process.
The EANM has written and approved these guidelines to
promote the use of nuclear medicine procedures of high qual-
ity. These guidelines are intended to assist practitioners in
providing appropriate nuclear medicine care for patients.
They are not inflexible rules or requirements of practice and
are not intended, nor should they be used, to establish a legal
standard of care.
The ultimate judgment regarding the propriety of any spe-
cific procedure or course of action must be made by medical
professionals considering the unique circumstances of each
case. Thus, there is no implication that an approach differing
from the guidelines is below the standard of care. On the
contrary, a conscientious practitioner may responsibly adopt
a course of action different from that set forth in the guidelines
when, in the reasonable judgment of the practitioner, such
course of action is indicated by the condition of the patient,
limitations of available resources or advances in knowledge or
technology subsequent to publication of the guidelines.
Introduction
These guidelines update the 2009 EANM guidelines on the
diagnosis of pulmonary embolism (PE) [1, 2] for ventilation/
perfusion single-photon emission tomography (V/PSPECT).
Since the previous EANM guidelines, little new data has
emerged with regard to the technical aspects of V/PSPECT.
This document defines the role of V/PSPECT in the diagnosis
of PE and other cardiopulmonary diseases.
Pulmonary embolism
Nonthrombotic emboli may be septic, fat, amniotic fluid and
air. In this document, PE refers to venous thromboembolism
(VTE). PE is an important and treatable illness caused by
migration of thrombi to the pulmonary circulation, commonly
from the veins of the lower extremities (deep vein thrombosis:
DVT). PE can cause death in the acute phase or later through
chronic thromboembolic pulmonary hypertension.
Although independent VTE risk factors and predictors of
VTE recurrence have been identified, and effective primary
and secondary prophylaxis is available, the occurrence of
VTE seems to be relatively constant, or even increasing [3].
Timely and accurate PE diagnosis is, therefore, essential.
Natural history of PE
The natural history of VTE has been extensively studied.
Measurements of fibrinogen uptake were used by Kakkar
et al. in the study evidencing that DVT developed in 30% of
132 patients undergoing surgery without prophylaxis [4]. In
most patients, DVT developed in the calf veins, propagating
to the proximal leg veins in 13%. Forty-four percent of pa-
tients with proximal DVT developed PE. Evidence that DVT
and PE are distinct manifestations of the same disease process,
referred to as VTE, has been provided by observations show-
ing that in the majority of patients with PE, DVT can be
detected using sensitive methods. In patients with proven leg
vein DVT, 40% have asymptomatic PE [5]. However, where-
as VTE can present with one or both of these two manifesta-
tions, DVTand PE, epidemiological differences between both
are important. Mortality is higher for PE than for DVT [6].
The International Cooperative Embolism Registry [7] aimed
at determining baseline mortality rates and mechanisms of
death reported a 3-month overall mortality rate of 15%; the
factors significantly associated with increased mortality being
systolic arterial hypotension, congestive heart failure, cancer,
tachypnoea, right ventricular hypokinesia, COPD and age >
70 years. Resolution of PE is variable. Evidence shows that a
majority of patients have unresolved PE at 6 months from
diagnosis [8]. Others report rapid resolution of a large PE
within hours of the onset of heparin therapy [9]. Fredin and
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Arborelius evidenced complete restoration of lung perfusion
in patients with PE within 1 week of diagnosis [10]. Based on
this rapidly changing pattern of perfusion in PE, Coakley rec-
ommended that imaging tests for PE diagnosis should be car-
ried out as soon as possible, preferably within 24 h after onset
of symptoms [11].
Epidemiology
Venous thromboembolism is a major cause of morbidity, mor-
tality and hospitalisation [3, 12–14]. A model based on data
from 6 European countries with a combined population of 310
million found approximately 466,000 cases of DVT and
296,000 cases of PE in 2004. These resulted in approximately
370,000 deaths, of which 7% were thought to be from diag-
nosed and treated VTE, 34% from sudden fatal PE and 59%
from PE following undiagnosed VTE [3]. Incidence for DVT
and PE increases with age. VTE is rare prior to late adoles-
cence [12, 15, 16].
One-third of PE episodes occur without any known risk
factor and are classified as ‘unprovoked’ [17]. The remaining
‘provoked’ PE episodes are secondary to a risk factor that may
be temporary (e.g. surgery, trauma, immobilisation, pregnan-
cy, oral contraceptive or hormone replacement therapy) or
persistent (e.g. cancer or inherited thrombophilia) [12, 18,
19]. About 20% of all VTEs are cancer-related [20]. Surgery
and immobilisation each account for 15% of cases [21]. Not
infrequently, PE is without clinical manifestations [22].
The most frequent inherited risk factors are factor V and
prothrombin (factor II) gene mutations. These have a
European prevalence of 3–7% and 1–2%, respectively [23].
Following a PE, about one-third of patients show persistent
pulmonary perfusion defects [24–26]. Chronic thromboem-
bolic pulmonary hypertension (CTEPH) is the principal
long-term complication of PE with an incidence of 0.1–4%
[27].
PE frequently recurs, usually after discontinuation of
anticoagulation (13% at 1 year, 23% at 5 years and 30% at
10 years) [12]. Recurrence rate is higher after unprovoked
VTE than after provoked VTE and higher after multiple epi-
sodes compared with a single event [12].
Pathophysiology
When unperfused regions are ventilated, there is an increase in
the dead space [28]. This is one of the reasons for dyspnoea.
Hypoxia, frequently present in major PE, is caused by several
mechanisms. The emboli occluding pulmonary end arteries
alter the local equilibrium and, therefore, can lead to haemor-
rhage, atelectasis, pleural effusion and pleuritic pain. The lung
has no pain fibres; thus, pain in PE is a symptom consequence
of the involvement of the parietal pleura.
Moreover, there is also increased pulmonary vascular resis-
tance that can produce right ventricular strain and failure,
electromechanical dissociation, hypotension, syncope and
sudden death. Pressure increase in the right atrium may lead
to right-to-left shunt through a patent foramen ovale, contrib-
uting to hypoxaemia. The shunt can also produce paradoxical
emboli, resulting in infarctions from venous thrombi in the
systemic circulation, commonly the brain [29–31].
Clinical presentation
The clinical signs of PE range from asymptomatic to sudden
death [12, 22]. Most patients with PE have symptoms includ-
ing dyspnoea, tachypnoea, chest pain (pleuritic or
retrosternal), cough, fever, haemoptysis, syncope, unilateral
leg pain or swelling, palpitations, tachycardia or dizziness
due to hypotension [32, 33]. Arterial hypotension and shock
are rare signs indicating central massive PE and/or a severely
reduced haemodynamic reserve, and these clinical signs and
symptoms indicate high-risk PE. It is associated with particu-
larly high early mortality [31]. In the case of central PE, chest
pain may have the characteristics of angina, probably because
of right ventricular ischemia, and poses the problem of differ-
entiating PE from acute coronary syndrome and aortic dissec-
tion [31].
The clinical features of PE are also common in patients
without PE [32, 33], and the prevalence of PE in patients with
clinically suspected VTE is only about 20% [34, 35].
Therefore, there is a risk that an undue number of patients
might receive an unnecessary imaging procedure. Thus, as-
sessments of clinical PE probability and D-dimer testing are
important steps in clinical practice to guide decisions about
who should be referred for imaging [31, 36]. The chest radio-
graph is useful for alternative diagnoses such as pneumotho-
rax, pneumonia, COPD, lung cancer or pulmonary fibrosis.
Assessment of pretest clinical probability
Clinical probability for PE can be assessed empirically by
clinical judgement (holistically) or by clinical prediction rules,
foremostWells’ and the revised Geneva scores [37, 38], which
have been adequately validated [34, 35, 39] and recommend-
ed by EANM, the Society of Nuclear Medicine andMolecular
Imaging and the European Society of Cardiology (ESC) [31,
40]. For both scores, simplified and validated versions are
available [39, 41–44]. Usually, patients are clinically stratified
into two or three risk categories: unlikely/likely and low/inter-
mediate/high with increasing prevalence of PE [45].
D-dimer testing
Plasma D-dimer (a breakdown product of fibrin clot) is not
only regular ly elevated in pat ients with venous
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thromboembolism but also in myocardial infarction, stroke,
infection, inflammation, cancer and pregnancy. The specifici-
ty of D-dimer is, therefore, low, and a positive D-dimer test
does not confirm PE. However, the D-dimer test is very sen-
sitive. Therefore, when the D-dimer is below a predefined cut-
off value (i.e. < 500 μg/L with correction for age), it can be
used to exclude PE in patients with either low to intermediate
or unlikely clinical probability [31, 46]. However, in old and
persistent PE, D-dimer can be negative. In patients with a high
or likely clinical probability, the D-dimer has no discriminating
power and should not be measured [47].
In a recent randomised clinical trial including 1916 patients
with suspected PE, considered by clinical judgement
(holistically) to be at very low risk for PE, the use of the pul-
monary embolism rule-out criteria (PERC) safely excluded PE
[48]. The PERC strategy may reduce the number of D-dimer
tests in patients with very low clinical probability of PE [48],
although caution is advised in using the PERC rule [49].
Imaging tests
In patients with a low or intermediate clinical probability but
positive D-dimer, and in patients with a high or likely clinical
probability, lung imaging is required. The two mainly used
imaging modalities are as follows:
& V/P imaging with SPECT (V/PSPECT) or in rare situations
planar scintigraphy (V/Pplanar). Occasionally, perfusion-
only lung scanning is performed. V/PSPECT may also be
combined with low-dose computed tomography (CT),
V/PSPECT/CT
& Computed tomography of the pulmonary arteries (CTPA)
Invasive pulmonary angiography is no longer regarded as
the gold standard for the diagnosis of PE because of its limited
sensitivity and specificity and wide interobserver variability
[50].
Transthoracic echocardiography was discussed in the for-
mer guidelines in haemodynamically unstable patients [1, 2].
In a recent review, the need for further research on this topic is
underlined [51].
Basic principles of PE diagnosis
PE leads to loss of perfusion to the area corresponding to the
volume supplied by the occluded end artery that may be a
whole lung, a lobe, a lung segment or a subsegment. In gen-
eral, the bronchial circulation maintains viability of the
embolised volume, and ventilation remains largely intact.
Accordingly, V/PSPECT exploits the unique pulmonary arterial
segmental anatomy. Figure 1 presents a segmental map, and a
case with PE is shown in Fig. 2.
PE is in general an acute disease that should be diagnosed
and treated without delay. V/PSPECT should, therefore, be per-
formed according to a 1-day protocol. V/Pplanar should only be
used when a patient for any reason cannot be examined by
V/PSPECT.
Radiopharmaceuticals for V/PSPECT
Ventilation
Ventilation can be evaluated with the 99mTc-labelled aerosols,
DTPA and Technegas®, or krypton gas (81mKr) (Table 1).
Fig. 1 Segmental map of the two
lungs in four coronal slices and
two sagittal slices for each lung. A
bronchopulmonary segment is
conical with its apex towards the
hilum and its base projected onto
the pleural surface. Thrombi
occluding pulmonary arteries,
therefore, produce characteristic
lobar, segmental or subsegmental
peripheral wedge-shaped defects
with the base reaching the pleural
surface
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99mTc-DTPA (99mTc-diethylen-tetraamino-pentaacetate) is
aerosolised from a water solution with a particle size of 1.2–
2 μm. 99mTc-DTPA allows studies of alveolo-capillary perme-
ability [58].
Technegas® is an aerosol of 99mTc-labelled solid graphite
hydrophobic particles, with a diameter of about 0.005–0.2 μm
[59]. The particles tend to grow by aggregation and should,
therefore, be used within 10 min after generation [60]. The
particle size is so small that the aerosol behaves nearly like a
gas until it arrives at the periphery of the lung where the
particles are deposited in bronchioli and alveoli, mostly by
diffusion. Technegas® greatly reduces the problem of central
deposition often encountered with 99mTc-DTPA. Technegas®
facilitates interpretation, particularly in COPD [58]. Hotspots
are nevertheless seen in patients with severe airway obstruc-
tion. The penetration index for Technegas® may be used for
grading of COPD severity [61, 62].
Krypton gas (81mKr) is an inert radioactive gas delivered
from an 81Rb/81mKr generator. 81mKr has a half-life of 13 s.
81mKr is inhaled until it reaches a steady-state activity in
the alveoli and then continuously during the whole imag-
ing procedure. Due to the higher gamma energy (190 keV)
of 81mKr compared with 99mTc (140 keV), ventilation and
perfusion images can be acquired simultaneously. Because
elimination of 81mKr from the alveoli is largely due to
decay of the isotope rather than by expiration, regional
activity at steady state accurately represents regional ven-
tilation. In COPD, the inhalation time to reach steady state
may, however, be too long to reach steady state. As the
half-life of 81Rb is only 4.6 h, the need for daily delivery
of the expensive cyclotron-produced generator limits the
clinical use of 81mKr.
Perfusion
For perfusion scintigraphy, intravenously injected macroag-
gregates of 99mTc-labelled human albumin (MAA) with a
diameter of 15–100 μm are nearly universally used.
Intravenous injection of MAA leads to microembolisation
of pulmonary precapillary arterioles and capillaries. Whilst
Fig. 2 Coronal slices in a patient
with PE. Multiple bilateral
segmental perfusion defects (red
arrows) in areas with normal
ventilation. These are delineated
on V/P quotient images which
facilitate interpretation
Table 1 Dosimetry of
radiopharmaceuticals used for
V/PSPECT
Radiopharmaceutical Administered activity
(MBq)
Critical organ
(mGy/MBq)
Effective dose
(mSv/MBq)
99mTc-MAA [52] 40–120 0.067 lungs 0.017
99mTc-DTPA [53] 20–30 0.047 bladder 0.007
99mTc-Technegas [54] 20–30 0.11 lungs 0.015
81mKr [55] 40–400 0.0068 lungs 0.0007
The biological half-life of 99m Tc-DTPA is 55–108 min [56] and of 99m Tc-Technegas 135 h [57]
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60,000 particles may suffice to reflect regional perfusion [63],
about 400,000 labelled particles are usually injected. This
leads to obstruction of a very small fraction of pulmonary
vessels. Injection of no more than 100,000–200,000 particles
is recommended for patients with known pulmonary hyper-
tension, right-to-left heart shunt, pneumonectomy or after sin-
gle lung transplantation. In infants and children, the number
of particles is recommended to be further reduced according
to weight [64].
Because of religious beliefs, it may be advisable to inform
patients that MAA is a blood product.
Quality control and injection practice
As radiochemical purity varies, supernatant activity
should be determined. As particles tend to settle, the vial
should be shaken before use. Withdrawal of blood into the
syringe should be avoided, as this will cause aggregation
of MAA particles resulting in artefactual hotspots. The
MAA suspension should be injected over 30 s, i.e. over
several breaths, to promote distribution reflecting regional
pulmonary perfusion. Patients should be in a supine posi-
tion during inhalation, intravenous injection and during
scanning.
Imaging protocols
Using aerosols, imaging starts with the ventilation scan,
immediately followed by the perfusion scan, according to
principles based on an extensive analysis serving to opti-
mise radioactivity doses, the relationship between activities
and scanning time for ventilation and perfusion, type of
collimator, number of rotational steps, matrix size and im-
age reconstruction algorithm [65] (Table 2). Activities of
25–30MBq and 140–160MBq are sufficient for ventilation
and perfusion studies, respectively, with a general-purpose
collimator, 64 × 64 matrix and 60–64 rotational steps of a
dual head gamma-camera, i.e. 120–128 projections [65,
66]. Time per projection should be 10 s for ventilation
and 5 s for perfusion studies.
This principle leads to the lowest radiation exposure con-
sistent with adequate image quality and, therefore, is in accor-
dance with good medical practice. It is applied in commercial-
ly available software and hardware systems and is recom-
mended in these guidelines. Deviations from these validated
standards require complementary documentation. The use of
low-energy high-resolution (LEHR) collimators would re-
quire either longer acquisition times or higher activities.
Iterative reconstruction is essential, e.g. ordered subset ex-
pectation maximisation (OSEM). For comparison between
ventilation and perfusion including triangulation, the patient
must be in the same position for the whole image acquisition.
Perfusion-only scintigraphy is recommended as a first step
during the first 3 months of pregnancy and in the case of
suspected massive PE (see below).
Image presentation
Standard software allows image presentation in coronal,
sagittal and transverse projections as well as the presenta-
tion of rotating 3D images (Segami, Hermes, GE and
others). Ventilation/perfusion quotient images may be de-
rived from the primary images [65, 66]. Ventilation counts
are normalised to perfusion counts before V/P quotient im-
ages are calculated. V/P quotient images facilitate diagnosis
and quantification of PE extension. As attenuation is the
same for ventilation and perfusion, V/P images do not re-
quire attenuation correction.
For quality control and fast orientation, an overview of
ventilation and perfusion in coronal and sagittal slices is
useful. For identification of matched and mismatched ven-
tilation and perfusion changes and particularly for calcula-
tion of V/P quotient images, it is essential that ventilation
and perfusion images are carefully aligned to each other. An
example is shown in Fig. 2 of a patient with PE and multiple
segmental perfusion defects, well delineated on V/P quo-
tient images. This is facilitated by the one-session protocol
Table 2 Summary of ventilation/perfusion protocol for V/PSPECT. Patients should be in a supine position during inhalation, intravenous injection and
during scanning
Ventilation Perfusion
Administration Inhalation Intravenous injection
Radiopharmaceutical administered activity Technegas® or DTPA 25–30 MBq to reach the lung 99mTc-MAA 120–160 MBq
Particle size 0.005–0.2 μm or 1.2–2 μm 15–100 μm
Time of imaging ≈ 11 min ≈ 5 min
Acquisition protocol General purpose collimator: 64 × 64 matrix, 60–64 steps
for each head, 5 s/step (V) 10 s/step (P) [65, 66]
Reconstruction Iterative reconstruction, e.g. OSEM with 8 subsets and 4 iterations
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with the patient in an unchanged position. Although help-
ful, V/P quotient images are not a prerequisite for high
quality V/PSPECT. The option to triangulate between coro-
nal, sagittal and transverse slices is valuable.
Interpretation and reporting of findings
Ventilation/perfusion patterns
For V/PSPECT, interpretation criteria are as important as the
imaging technique itself. Studies based on probabilistic
reporting of planar imaging (PIOPED I) show high rates
of nondiagnostic reports. In contrast, V/PSPECT with holis-
tic interpretation (Table 3) is associated with very low rates
of nondiagnostic reports and allows a diagnostic conclu-
sion that is binary with respect to PE. All ventilation and
perfusion patterns as well as the extent of defects should be
described. A few patients might show widespread V/P ab-
normalities not specific for any disease.
Criteria for acute pulmonary embolism
The recommended basic criteria for reading V/P scintigraphy
are the following:
Table 3 Semiology of lung ventilation/perfusion pathology with V/PSPECT. Interpretation and differential diagnosis
Semiology Diagnosis Probability that the
semiologic pattern is
diagnostic
Level of evidence
Pattern Distribution Area
Mismatch Segmental 1 segment PE* Very high
≥ 2 subsegments PE* Very high
≤ 1 subsegment Non-PE High
Total lung
unperfused
Total lung Tumour# High
Abscess# High
Massive PE Very low (rare) Very rare condition
Nonsegmental Systematically antigravitational
redistribution
Heart failure High
Irregular Vasculitis Very low (rare) Very rare condition, expert
opinion
Match Segments or
lobules
No stripe sign Tumour Depends on
clinical contextAtelectasia
Empyema
Stripe sign Pneumonia
evolutioned stage
High
Reverse
mismatch§
Segments or
lobules
Stripe sign Pneumonia initial
stage
High
No stripe sign COPD High
*Even in the presence of concomitant pathologies
# Recommend CTPA
§More reduction of ventilation than perfusion
PE:
• V/P mismatch of at least one segment or two subsegments in keeping with the pulmonary vascular anatomy (wedge-shaped defects with the base
projecting to the lung periphery).
No PE:
• Normal perfusion pattern in keeping with the anatomic boundaries of the lungs.
• Matched or reversed-mismatched V/P defects of any size, shape or number in the absence of mismatch.
• Mismatch that does not follow a lobar, segmental or subsegmental pattern.
Nondiagnostic for PE:
• Widespread V/P abnormalities not typical of specific diseases.
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As proposed in the 2009 EANM guidelines, the diagnostic
cut-off to consider a V/PSPECT positive for PE should be 1 seg-
mental or 2 subsegmental mismatched defects. This principle is
further supported [67], and its safety was confirmed in large
studies [67–69]. A single subsegmental mismatched perfusion
defect should be reported but does not fulfil diagnostic criteria
for PE. In some cases, PE may be found on CTPA in such
patients, but clinical significance is not documented.
Pulmonary arteries and capillary beds uniquely possess fibrino-
lytic properties that both trap and lyse small subsegmental clots,
suggesting that small PEs are a common physiological
phenomenon.
Recommendations from the ESC suggest an individualised
approach; patients can be managed conservatively if the pres-
ence of deep vein thrombosis has been excluded [56]. Patients
with a Wells score > 4 have a 4-fold increased risk of adverse
outcome with one or multiple emboli in subsegmental arteries
[70].
Applying these principles of interpretation, recent
V/PSPECT studies amounting to over 5000 cases report a neg-
ative predictive value of 97–99%, sensitivities of 96–99% and
specificities of 96–98% for PE diagnosis. Rates of
nondiagnostic findings were 1–4% [61, 68, 69, 71–78].
Pitfalls in the interpretation of V/PSPECT
As with any diagnostic test, it is vital that the reporting phy-
sician has the knowledge of a number of sources of error.
These include the following:
& Technical artefacts may arise from preinjection handling of
the 99mTc-MAA. The withdrawal of blood into the syringe
that contains the solution of 99mTc-MAA can cause the ag-
gregation of particles that can produce hotspots in the im-
ages. A similar consequence can appear from failure to re-
suspend 99mTc-MAA particles before the administration.
& Planar imaging may underestimate the presence or extent of
perfusion abnormalities because of normal perfusion
masking embolised regions, also known as the shine through
of normal areas. This problem is eliminated by V/PSPECT.
& Technegas® is preferred over liquid aerosols in patients
with COPD. Moreover, in rare patients with emphysema,
Technegas® particles are trapped in bullae in which per-
fusion is absent. This causes a pattern that may be mistak-
en for a mismatch [76, 79].
& In rare cases, vasculitis and congenital vascular anomalies
may lead to segmental/lobar mismatches.
& Mismatched perfusion defects without a clear segmental
character may be seen in older, partly resolved PE, but not
related to acute PE. These nonsegmental mismatched de-
fects are observed in several lung disorders including lung
cancer, mediastinal lymphadenopathy, postradiation
pneumonitis/fibrosis and heart failure. V/PSPECT facilitates
the identification of segmental perfusion defects, which
are particularly well visualised when using rotating 3D
volumetric images.
& Unilateral absence of perfusion in a whole lung with pre-
served ventilation and without any V/P mismatch in the
other lung is generally not due to PE [80, 81]. In such cases,
chest CTmay reveal the presence of other pathologies such
as tumour, aortic dissection, other mediastinal processes or
congenital pulmonary vascular abnormalities.
& The ‘rind’ artefact seen in ventilation SPECT represents a
band of increased activity along the posterior (dependent)
portion of the lung. This is probably produced by dynamic
changes in the lung volume during the acquisition [57, 82].
& Fissure artefacts are a common finding along the line of
the oblique fissure, especially in perfusion SPECT. It may
produce a nonsegmental mismatch [57].
Additional considerations
Quantification of PE extent
The extent of PE is an independent risk factor for PE recurrence
[83–85]. Quantification of PEmay be useful for themanagement
of patients with acute PE [86]. V/PSPECT is particularly suitable
for quantification. The number of segments and subsegments
indicating mismatch typical of PE can be counted and expressed
as a percentage of the total lung parenchyma. However, as the
volume of each segment and subsegment is different, this calcu-
lation is approximate providing a semiquantification of the per-
centage of the total lung parenchyma affected. Furthermore, areas
with ventilation abnormalities can be recognised allowing for the
assessment of the degree of total lung function affected. In hae-
modynamically stable patients with PE, outpatient management
is safe provided that the embolic burden, quantified using
V/PSPECT, is included in the treatment decision algorithm [86].
Follow-up
The natural history of PE is still not well known. Alternative
strategies for PE therapy should be studied, regarding therapy
duration and choice of drugs in different categories of patients.
The issue of small emboli is particularly relevant, as the need
for treatment is not properly supported by evidence. Figure 3
presents a patient with untreated small PE who developed
chronic PE after 3 months of follow-up.
Follow-up of PE using imaging is essential to:
& Assess therapy effect
& Differentiate between new and old PE when there is a
suspicion of PE recurrence
& Explain physical incapacity after PE
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Some patients tend to develop recurrent episodes of PE.
Figure 4 presents a patient with recurrent PE, shown by
follow-up scans. Without both initial and follow-up images,
it is often impossible to differentiate between old and new
PE. The risks in patients treated with thrombolysis for mas-
sive PE include not only bleeding but also those related to
unresolved PE. Immediate imaging control provides objec-
tive information on the need for repeated thrombolysis.
Symptomatic patients with small emboli are diagnosed with
sensitive methods, particularly V/PSPECT. Figure 5 presents
a case with PE in the middle lobe and pneumonia in the
posterior right lung which could not have been identified
without SPECT and ventilation images.
The natural history and the efficacy of treatment in this
group of patients is rather unknown. Thus, follow-up is indi-
cated to individualise therapy [87–89].
Fig. 3 Sagittal slices of both
lungs in a patient with small PE
(red arrows), initially (not treated)
and 3 months later. On follow-up,
the progression of perfusion
defects as well as deterioration in
the ventilation (blue arrow in the
left lung) can be seen clearly. The
patient also developed pneumonia
Fig. 4 Coronal slices in a patient
with recurrent PE (red arrows),
initially referred after a diagnosis
of pulmonary hypertension. PE
was not identified on CT. The first
follow-up scan shows new perfu-
sion defects that occurred after
stopping therapy, and the final
follow-up identifies improving
perfusion after 4 months of
treatment
Eur J Nucl Med Mol Imaging (2019) 46:2429–2451 2437
The requirements that should be met by a method used for
follow-up are as follows:
& Applicability to all patients
& Low radiation dose
& High sensitivity to allow estimation of resolution of even
small emboli and occurrence of new ones
V/PSPECT seems ideally suited for follow-up of PE because
small and large emboli are both recognised, allowing a de-
tailed study of regression or progression of the thrombotic
disease [87–89]. Furthermore, the low radiation exposure en-
ables repeat studies. Obviously, using the same method for
diagnosis and follow-up is advantageous. Research in this area
is especially indicated and a predischarge V/PSPECT can be
recommended to help identify patients in need of life-long
treatment.
V/PSPECT/CT
The introduction of integratedmultimodality SPECT/CTcam-
eras has enabled simultaneous acquisition of V/PSPECT and
CT, V/PSPECT/CT [52–55, 90].
The CT is usually performed as a low-dose CT scan
without contrast enhancement. The additional radiation
dose is approximately 1–2 mSv, so that the whole
V/PSPECT/CT acquisition results in approximately 3–
4 mSv. To reduce misalignment between the SPECT and
CT images, it is proposed that CT scans are acquired during
continuous shallow breathing [55]. Obviously, this will af-
fect evaluation of structures particularly in basal regions,
causing artefacts.
V/PSPECT/CT has similar sensitivity as V/PSPECT but slightly
higher specificity for PE [52, 91]. Low-dose CTmay visualise
nonthromboembolic abnormalities such as emphysema, pneu-
monia and other parenchymal changes or extrinsic vascular
compression, which may explain perfusion defects. Figure 6
presents a case with COPD, emphysema and a mediastinal
tumour. CT acquired during a full-dose breathhold scan also
has disadvantages with artefacts originating from the move-
ment of the bronchi. CT image acquisition type is dependent
on the capabilities of the scanner used.
Using low-dose CT instead of ventilation images approxi-
mates the sensitivity for PE compared with V/PSPECT/CT but
has a higher rate of false positives [52, 91, 92].
Fig. 5 Sagittal slices of the left lung in a patient with PE in the medial
lobe (red arrow) and pneumonia posteriorly (blue arrow). The VP
mismatch may be highlighted in V/P quotient images
Fig. 6 A patient with COPD, emphysema and tumour. Coronal slices
display uneven distribution of ventilation with a pattern of deposition of
99mTc-Technegas® that is typical for COPD. Perfusion follows the
ventilation pattern. Matched ventilation and perfusion defects are
observed in both upper lobes (green arrows) and to the right of the
mediastinum (orange arrows). In the medial row of the corresponding
coronal CT slice, emphysema is seen in both upper lobes (green
arrows), as is a tumour in the mediastinum (orange arrow). Fusion
images of CT and ventilation SPECT and CT and perfusion SPECT are
shown
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Further studies of V/PSPECT/CT to define its value according
to good clinical practice in various categories of patients seem
merited. In patients with COPD, the added value of V/PSPECT/
CT has been validated [93].
CTPA
Computed tomography angiography of the pulmonary artery
(CTPA) is imaging of the pulmonary arteries during the pas-
sage of intravenously injected iodinated contrast material.
Pulmonary emboli are visualsed as so-called filling defects
caused by emboli within otherwise homogenously contrast-
filled pulmonary arteries. CTPA is easy to perform in a few
minutes.
CTPA needs to be embedded in decision strategies that are
based on the assessment of clinical PE likelihood [31]. CTPA
confirms the diagnosis of PE in clinically high probability
patients (PPV > 95%). In the case of high pretest probability
of PE and a negative CTPA, current data on diagnostic accu-
racy are inconsistent [94–96]; CTPA is overused in a great
number of patients with low prevalence of PE [97, 98]. A
PE located centrally in the pulmonary circulation can be de-
tected by CTPAwith a high PPV. The PPV decreases at seg-
mental and subsegmental levels [96]. When clinical probabil-
ity of PE is low or intermediate, CTPA may overdiagnose PE,
leading to a low NPV [96].
CTPA has the potential to visualise additional pathologies
other than PE such as pneumothorax, pneumonia, interstitial
lung disease, pleural disease, aortic dissection and pathologies
of the spine and rib cage. In the case of PE, CT is able to depict
signs of right heart strain which is of prognostic importance
[99–101].
Risks of CTPA
The contraindications for CTPA are linked to the use of iodin-
ated contrast media:
& Iodine hypersensitivity. Severe pseudoallergic reactions
are generally very rare (approx. 0.04%, rarely fatal
[102]). In an emergency scenario when CT cannot be
withheld, intravenous premedication may be suitable.
& Thyroid dysfunction. Induction of hyperthyroidism and
in rare cases also hypothyroidism is another complica-
tion associated with iodinated contrast media [103]. In
an iodine-deficient geographical region, 2% of patients
developed subclinical hyperthyroidism [104]. In unse-
lected patients, overt hyperthyroidism occurred in
0.25% within 12 weeks [105]. Iodine-induced thyrotox-
icosis is often overlooked in the elderly [106], and in the
worst case, it may even cause a thyroid storm with car-
diac arrest [107]. Risk factors are (potentially undiag-
nosed) Graves’ disease and/or thyroid autonomy [108].
Patients with thyroid storm should not receive iodinated
contrast media at all; in other cases, premedication with
oral sodium perchlorate (and thiamazole) may be help-
ful. Under emergency conditions, this treatment may be
initiated directly after contrast exposure. Thyroid func-
tion is routinely monitored prior to contrast application
in the vast majority of radiological institutions through
serum baseline TSH.
& Renal dysfunction. The most severe complication of
CTPA is contrast media-induced nephropathy (CIN) or
contrast-induced acute kidney injury (CI-AKI). CI-AKI
is defined as an increase in serum creatinine within 48–
72 h after intravenous administration of low- or
isoosmolarity iodinated contrast media. It carries a risk
of chronic renal insufficiency, dialysis and death [100,
109]. The assumption of causality between intravenous
contrast media administration and AKI has been chal-
lenged in recent publications, but data are controversial.
The baseline glomerular filtration rate (eGFR) was
found to be an independent predictor of AKI [110]. In
two multivariate analyses, patients with an eGFR ≤
43.6 mL/min [111] or eGFR < 60 mL/min [112], respec-
tively, had the potential to develop CI-AKI. The odds
ratios in the incidence of CI-AKI between contrast-
enhanced CT and noncontrast CT increased below an
eGFR < 30 mL/min [113]. In two meta-analyses,
contrast-enhanced CT, compared with non-contrast-
enhanced CT, was not significantly associated with
AKI [114, 115]. In a large single-centre retrospective
cohort study, the probability of developing AKI was
10.6%, 10.2% and 10.9% in the contrast-enhanced,
unenhanced and non-CT group [116]. However, a se-
lection bias must be considered as only a minority of
patients with a baseline serum creatinine > 1.5 mg/dL
received contrast media and factors that may have in-
fluenced the clinical decision to administer contrast me-
dia could not be perceived. Randomisation of patients
to receive intravenous contrast media, once not consid-
ered ethically feasible, will be necessary to fully under-
stand the role of contrast media in precipitation of renal
dysfunction [116]. Current guidelines consider intrave-
nous contrast administration to be safe to a creatinine
clearance of 30 mL/min/1.73 m2 [117]. In almost every
radiological institution, a baseline serum creatinine lev-
el and/or eGFR is determined prior to intravenous con-
trast administration to identify patients at risk. CI-AKI
was considered to be the third most common cause in
hospital acquired AKI [118]; now strong evidence is
provided that the incidence of CI-AKI is substantially
lower [109]. AKI is a multifactorial entity, and usually
more than one risk factor (contrast media, nephrotoxic
drugs, hypertension, age > 70 years, reduced cardiac
output, diabetes mellitus and others) is involved [102].
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Comparison of V/PSPECT and CTPA (see also Table 4)
Availability CTPA is available in nearly all medical centres
and community hospitals, often on a round-the-clock basis.
V/PSPECT is available in fewer hospitals and seldom on a 24-
h basis. CTPA has been advocated for patients with suspected
PE and signs of shock or hypotension [31].
Feasibility and rate of nondiagnostic studies Feasibility of
CTPA is restricted by the need to use intravenous iodinated
contrast media. Whilst the general risk of CI-AKI seems to be
overestimated [109] and iodine-induced thyrotoxicosis may
be prevented by premedication, the residual risks are of a
serious nature. Elevated serum creatinine and a suppressed
TSH are relative contraindications to CTPA provided that
V/PSPECT is available [52, 96]. High flow rates of contrast
medium are a precondition for CTPA, but cannot be achieved
in all patients. Motion artefacts reduce spatial resolution. In
the PIOPED II trial, CTPA was inconclusive in 6.2% of pa-
tients because of poor image quality, in a subgroup this was
10.6% [96]. An increase of detector rows in CT improves
resolution of CTPA, but the number of inconclusive results
remained at 10% in both the 4-row and 64-row cohort, mostly
due to movement artefacts and suboptimal contrast
opacification [47]. In pregnant patients and those with a very
low prevalence of PE (3.3%), inconclusive results were seen
in 5.9% [129]. Nondiagnostic studies with V/PSPECT may be
obtained with conventional radioaerosol in patients with se-
vere COPD, but this restriction has been mostly eliminated by
the use of Technegas® [68, 69, 119, 120]. In conclusion, if
contrast media-related risks are considered, feasibility of
CTPA is restricted in many more patients than with V/PSPECT.
In haemodynamically unstable patients, CTPA is often rec-
ommended [31, 130]. However, if a gamma camera is avail-
able, perfusion-only scintigraphy, even a single planar image,
is adequate to exclude massive PE [130].
Accuracy of PE diagnosis
The lack of a satisfactory gold standard for making the
diagnosis of PE poses difficulties for the assessment of
sensitivity, specificity and accuracy of all diagnostic
methods. Follow-up of patients for recurrence of PE as a
predictor of false negative results may overcome this lim-
itation. The comparison of V/PSPECT and CTPA shows con-
troversies. On one side, no performance difference be-
tween V/PSPECT and CTPA was seen [121]. In other stud-
ies, V/PSPECT is proposed to be superior to CTPA in cases
with other underlying lung diseases preventing the diagno-
sis of PE with CTPA. V/PSPECT more often provided a
diagnosis of PE in patients with high clinical suspicion of
PE and in the presence of indeterminate CTPA imaging
(sensitivity 93% vs. 83%) [68, 94, 131, 132].
Another available benchmark is follow-up of patients for
recurrence of PE as a predictor of false negative results. An
equivalent of sensitivity was calculated on the basis of a 3-
month follow-up in 14,545 patients where PE was excluded
by CTPA [48, 94, 95, 133–138] and in another 1865 patients
where this was done by V/PSPECT [52, 74, 75, 139]:
Sensitivity equivalentð Þ %½  ¼ PE prevalence %½ −VTE relapse rate %½ 
PE prevalence %½  •100
The mean sensitivity (equivalent) was > 95% for the
both methods. The results do not reflect true sensitivity
of the imaging test, since most PE are single events, not
recorded by follow-up. On the other hand, sensitivities
derived from relapse rates clearly indicate that both
V/PSPECT and 16- to 64-row CTPA are able to recognise
larger PE with a tendency to recurrent episodes of PE. An
error rate of about 5% may be caused by false negative
results of the imaging test with subsequent PE relapse,
but may also reflect true negative results with subsequent
Table 4 Summary of the pros and cons for the two principal methods to diagnose PE
V/PSPECT CTPA Comment
Availability Limited Wide Makes CTPA indispensable
Feasibility Near 100% Up to 50% Makes V/PSPECT indispensable
Rate of nondiagnostic studies 1–4% [68, 69, 119,
120]
4–10% [47, 96]
Sensitivity ≥ 96% ≥ 78% In high clinical probability, 40% needs further
exam
Specificity ≥ 97% ≥ 98% V/PSPECT and CTPA equivalent
Effective radiation dose 1.2–2 mSv 4–20 mSv [121–127]
Absorbed breast radiation dose ≈ 0.8 mGy ≈ 12–44 mGy [79, 128] V/PSPECT crucial for young women
Additional diagnoses Common, important Common, important Highest documented rate—V/PSPECT
Diagnostics of chronic pulmonary
embolism
Reference method? Not useful but needed prior to
surgery?
V/PSPECT is gold standard
Follow-up and research Optimal V/PSPECT offers quantitative data
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primary PE events. Large multicentre management out-
come studies based on V/PSPECT with a standardised diag-
nostic algorithm defined a priori are needed to differentiate
this.
In a systematic review and meta-analysis, diagnostic
performance of V/PSPECT was equivalent to CTPA [121].
In head-to-head comparison studies, V/PSPECT was superi-
or to CTPA using ROC analysis [140]. This applies partic-
ularly in cases with other underlying lung diseases and
when the diagnosis of PE could not be established with
CTPA [68, 94, 132, 141]. V/PSPECT more often provided
a diagnosis of PE in patients with a high clinical suspicion
of PE and in the presence of indeterminate CTPA (sensi-
tivity 93% vs. 83%) [131]. Superior sensitivity of
V/PSPECT is best seen in patients with chronic pulmonary
embolism where V/PSPECT has reference status [142], but
CTPA and right heart catheterisation are also essential for
patient care.
In conclusion, both techniques display specific advan-
tages and shortcomings. V/PSPECT is superior to CTPA in
cases with underlying other lung diseases and when the
diagnosis of PE cannot be established with CTPA [68,
94, 131, 132].
Radiation exposure
A key objective of imaging PE is to minimise radiation
exposure without sacrificing image quality and diagnostic
accuracy. The amounts of radiation involved must be con-
sidered together with imaging protocols. Table 1 gives ba-
sic data on radiation exposure for V/PSPECT. With the rec-
ommended activities for ventilation and perfusion, the ef-
fective dose is 2 mSv.
In a systematic review and meta-analysis of the litera-
ture, radiation exposure was 2.12 mSv for V/PSPECT per
correct diagnosis compared with 4.96 mSv for CTPA
[121]. In clinical routine, radiation doses between 3.5 and
13.2 mSv have been reported for CTPA [122–124].
Automated data collection as volume CT dose index and
dose-length product, averaged to effective doses, varies
considerably within and across facilities. Primary factors
that influence dose variations are patient size (weight and
chest diameter), multiphase scanning and institutional pro-
tocol choices [125]. In general, higher effective doses (>
5 mSv) are reported from automatically collected data
[125–127].
The most critical organ in CTPA is the female breast.
Absorbed radiation doses to the female breast ranging from
8.6 to 44 mSv have been reported [79, 128, 143]. Tube
current modulation is able to decrease the breast dose from
51.5 to 8.6 mSv [143], whilst shielding is less effective
[144]. Absorbed radiation dose to the female breast from
V/PSPECT is < 1 mSv [79]. Fetal-absorbed doses for
V/PSPECT and CTPA are similar and so small that they are
unlikely to be clinically significant [79, 128, 145].
In conclusion, effective and absorbed doses are lower
for V/PSPECT than for CTPA. The difference is of particular
importance for the female breast, particularly in young
women and critically so during pregnancy. Fetal doses
are low and similar for both methods.
Additional diagnostic contributions
of V/PSPECT
Chronic obstructive pulmonary disease
A general unevenness of ventilation typical for COPD has
been observed in V/PSPECT in patients investigated for PE
[68, 120, 146]. Perfusion is usually less affected, which
leads to so-called reversed mismatch [62, 93, 119]. The
degree of ventilation defects reflects varying degrees of
obstruction with COPD. Figure 7 presents cases with dif-
ferent degrees of COPD [62, 68, 120, 147–149]:
Fig. 7 Schematic presentation of the obstructive lung disease grading
system and correlating representative V/PSPECT images that shows
different degrees of airway obstruction on coronal slices. 0: normal,
even distribution of Technegas® with good peripheral penetration and
without accumulation in large or small airways. 1: mild airway
obstruction, slightly uneven distribution with some deposition of aerosol
in small and intermediate airways. Only minor areas with reduced
peripheral penetration are observed. 2: moderate airway obstruction,
deposition of Technegas® in intermediate and large airways, diminished
peripheral penetration with maximum accumulation in the central half of
the lung. 3: severe airway obstruction, central deposition in large airways
with severely impaired penetration of Technegas® and major areas with
reduced or abolished function
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& Grade 1: uneven aerosol distribution through the lung seen
in mild COPD.
& Grade 2: uneven aerosol distribution and reduced
Technegas® penetration to the periphery, with deposition
of aerosols in small airways, seen as hotspots. This indi-
cates moderate COPD.
& Grade 3: a severely impaired Technegas® penetration to
the periphery and a central deposition of Technegas® in
large airways, usually with large areas of reduced/absent
ventilation. This indicates severe COPD. Figure 8 presents
a case with severe COPD, emphysema and PE.
Left heart failure
Antigravitational perfusion distribution is typical for pulmonary
congestion due to left heart failure. In supine patients, redistribu-
tion of perfusion towards anterior regions has been observed in
5–15% of patients with suspected PE [146, 150–152]. Based
upon ameasured vertical perfusion gradient, a positive predictive
value of ≥ 88% to detect pulmonary congestion has been report-
ed [151]. As ventilation is usually less affected, V/P mismatch
may be observed in dorsal regions. Figure 9 presents a case with
left heart failure initially and at the follow-up. This mismatch has
a nonsegmental pattern (Fig. 9). It does not conform to the anat-
omy of pulmonary vascular architecture and should, therefore,
not be misinterpreted as PE. V/PSPECT was recently validated
against right heart catheterisation for diagnosis of pulmonary
congestion in left heart failure [153].
Pneumonia
Pneumonia is a general term for conditions of lung inflammation
often caused by bacterial, viral or fungal infections. It presents
with nonspecific symptoms, and like other illnesses, this can lead
to diagnostic problems [154]. V/PSPECT shows ventilation de-
fects, which usually exceed perfusion defects (reversed V/P mis-
match) [155, 156]. Preserved perfusion along the pleural border
recognised as the ‘stripe sign’ is a specific sign of pneumonia [1,
157, 158]. Figure 10 presents a case with pneumonia on
V/PSPECT and chest X-ray. Such ventilation-perfusion patterns
in pneumonia have been documented with positron emission
Fig. 8 V/PSPECT images showing a severe degree of airway obstruction in
coronal and sagittal projections in a patient with severe COPD,
emphysema (green arrow) and PE (red arrow)
Fig. 9 Sagittal slices from the
lung show antigravitational
redistribution of perfusion in left
heart failure. Ventilation is less
affected causing mismatch. Mind
the pattern; it is not of segmental
character!
Eur J Nucl Med Mol Imaging (2019) 46:2429–24512442
tomography as well [159]. Reversed-mismatched or matched V/
P defects typical for pneumonia can be found in V/PSPECT in
patients who are studied for PE. Figure 5 presents a case with
PE and pneumonia. In some patients, V/P defects typical for
pneumonia reduce the total lung function in the absence of any
structural CT defects [146, 160]. Nevertheless, the potential of
V/PSPECT for diagnosis and management of pneumonia has in
general not been exploited.
Chronic pulmonary embolism and chronic
thromboembolic pulmonary hypertension
Chronic PE represents a condition inwhich perfusion defects due
to pulmonary emboli have not resolved. Its clinical presentation
is often insidious. It might be progressive and can lead to chronic
thromboembolic pulmonary hypertension (CTEPH), right heart
failure, arrhythmia and death. Figure 4 presents a case with re-
current PE and CTEPH. Figure 11 presents a case with chronic
PE. CTEPH might be a consequence of repeated unrecognised
small PEs. The incidence of CTEPH secondary to acute PE is
around 5% [27, 142, 161–163].
V/Pscan with a sensitivity of 96% and specificity of 90% is a
mainstay in the diagnosis of CTEPH, since CTPA has a sensitiv-
ity of only ≈ 50% [164]. The higher sensitivity of V/PSPECT
compared with CTPA has been confirmed [165]; agreement be-
tween CTPA and scintigraphy ranged from fair (κ = 0.31) to
slight (κ = 0.09) [166].
V/Pscan is the imaging test of choice to exclude CTEPH [142],
but is underused to diagnose CTEPH [167–169]. Pulmonary
scintigraphy might differentiate among different types of
CTEPH (Fig. 6).
After diagnosis of CTEPH, CTPA and right heart catheterisa-
tion are important for management decisions about therapy.
Lung cancer radiotherapy planning
Radiation therapy, alone or in combination with other treat-
ment, plays an important role in the management of lung can-
cer. ‘Functional image-guided lung avoidance radiotherapy’ is
Fig. 10 Sagittal slices of the left lung in a patient with extensive pneumonia in whom the chest X-ray was interpreted as showing atelectasis (a). The left
lung shows nearly absent ventilation in areas with much better perfusion. Arrow indicates stripe sign. V/P quotient highlight reverse mismatch
Fig. 11 Patient with chronic PE. The perfusion is only maintained in the
central part of the lung, leading to large nonsegmental perfusion defects
(red arrows)
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an emerging concept aimed at delivering a high radiation dose
to the lung cancer tumour volume whilst minimising irradia-
tion to the uninvolved functional lung tissue. In the future,
V/PSPECT could become an interesting technique to provide
the functional information needed for the planning of such
treatment [170].
Pregnancy
Pregnancy poses unique circumstances in diagnosing PE:
& The incidenceofPEinpregnancy isabout fivefoldhigher than
in nonpregnant females of a similar age and is the leading
nonobstetric cause of death during pregnancy in developed
countries. The incidence of PE and DVT is about 1 and 3‰,
respectively [171]. The incidence is similar in all 3 trimesters
[172]. The diagnostic accuracy of any test is compromised by
a low prevalence of PE in this collective [147, 173].
& D-dimer is not useful because it is elevated during preg-
nancy [174]. CTPA has a high rate of nondiagnostic tests
due to changed haemodynamics [175–179].
& CTPA leads to unique radiation hazards to the maternal
breast [180].
Imaging tests
Ultrasonography To avoid unnecessary irradiation, venous
compression ultrasonography can be considered. However,
the diagnostic yield can be low [145].
CTPAAn increased blood volume and cardiac output shortens the
arrival time of intravenous contrast in the pulmonary vessels,
necessitating adjustments in triggered scan delays [178, 181].
Transient influx of unopacified blood from the inferior vena cava
has also been identified as a cause for poor-quality CTPA [178,
182]. Nondiagnostic CTPA scans occur in 6–36% of patients,
whilst alternative diagnoses were identified in 2–13% [145, 178,
183, 184]. Prenatal exposure to iodinated contrast media is not a
risk factor for neonatal thyroid dysfunction [185].
V/PSPECT To minimise radiation, a 2-day protocol is recom-
mended. Perfusion-only SPECT is performed on day 1, with
only 50 MBq 99mTc-MAA. Because of the low incidence of
pulmonary disorders in pregnant women, PE is usually ex-
cluded based on a normal perfusion pattern [186]. In the case
of an abnormal perfusion pattern, anticoagulation therapy can
be started until a ventilation study is performed on day 2,
using a lung-deposited activity of 20–30 MBq. This strategy
leads to a high sensitivity and specificity of the examination
[145, 147]. After the first trimester, the standard 1-day
V/PSPECT protocol may be considered.
Dosimetry
Fetal doses for both CTPA and perfusion SPECT are ≤
0.12mGy [145, 187–190]. Thematernal absorbed dose, main-
ly to the breast, differs significantly and may range from 5 to
20 mSv for CTPA [121, 125, 127, 145, 191, 192] and 0.5–
0.8 mSv for V/PSPECT [145, 147].
Recommendation
If both imaging modalities are available, V/PSPECT is recom-
mended due to the following:
& Near 100% accuracy of the diagnostic test
& The considerably lower breast radiation dose [79, 128,
147, 189, 193]
& No contraindications
Diagnostic algorithm
The likelihood of PE is assessed using a clinical prediction
tool and, where indicated, the measurement of D-dimer.
Where acute PTE is suspected, patients should be treated
with heparin (unless contraindicated) until the test result is
known. The choice of imaging test will depend on local
availability but where possible V/PSPECT is preferred over
VPPLANAR. Few cases using V/PSPECT are nondiagnostic,
and in such instances, a further test (CTPA) is necessary to
confirm or exclude PE. V/PPLANAR has a higher indetermi-
nate rate, in which case further investigation (usually
CTPA) is necessary for diagnosis. At negative CTPA, fur-
ther test should be performed in patients with remaining
clinical suspicion of PE (blue arrow). With regard to the
availability of V/P (planar or SPECT), it is highly variable
depending on the hospital and country, but in many cen-
tres, the availability is not 24 h a day nor every day of the
week/year.
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1. ‘This guideline summarizes the views of the Cardiology
Committee of the EANM/European Association of
Vascular Medicine, experts in radiology and cardiology,
and reflects recommendations for which the EANM can-
not be held responsible. The recommendations should be
taken into context of good practice of nuclear medicine
and do not substitute for national and international legal or
regulatory provisions’.
2. ‘The guidelines were brought to the attention of all other
EANM Committees and to the European National
Societies of Nuclear Medicine. The comments and sug-
gestions from the EANM Committees and from the
European National Societies are highly appreciated and
have been considered for this Guideline’.
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